Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study

Hexsel Dermatology Clinic

Status and phase: Begins enrollment this month; Phase 2

Conditions: Nail Psoriasis

Treatments: Drug: Topical 2% Tofacitinib

Study type: Interventional

Funder types: Other

Identifiers

NCT07313072

12-DPCHD25-04

Details and patient eligibility

About

To evaluate the efficacy and safety of topical 2% tofacitinib nail lacquer in nail psoriasis, using the NAPSI and DLQI scales before and after 26 weeks of treatment.

Enrollment: 10 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Age ≥ 18 years;

• Presence of nail psoriasis in at least one fingernail or toenail;
• Patients not using systemic medication, or without adequate response to systemic medication after at least 6 months of use;
• Ability to read, understand, and sign the Informed Consent Form (ICF) and the Consent Form for Images, Presentations, and Scientific Publications.

Exclusion Criteria: Pregnant or breastfeeding women or those planning to become pregnant during the study period;

• History of sensitivity to any components of the study product;
• Initiation of systemic medication for nail psoriasis less than six months prior.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Medicated Nail Lacquer

Experimental group

Treatment:

Drug: Topical 2% Tofacitinib